Cargando…

Impact of sodium-glucose co-transporter 2 inhibitors on renal outcomes in patients of diabetes mellitus: A meta-analysis of landmark renal and cardiovascular outcome trials

Sodium-glucose co-transporter 2 inhibitors (SGLT2is) are recommended as the next step therapy for the management of diabetes mellitus. The large clinical trials of SGLT2is demonstrated benefits on various renal endpoints. We conducted this meta-analysis of large trials on cardiovascular and renal sa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bose, Debdipta, Maurya, Miteshkumar, Konwar, Mahanjit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10335648/ https://www.ncbi.nlm.nih.gov/pubmed/37313937 http://dx.doi.org/10.4103/ijp.ijp_342_21

Ejemplares similares

Vitamin D deficiency in rheumatoid arthritis patients of India – a single-arm meta-analysis
por: Bose, Debdipta, et al.
Publicado: (2023)

Efficacy and Safety of Liraglutide 3.0 mg in Patients with Overweight and Obese with or without Diabetes: A Systematic Review and Meta-Analysis
por: Konwar, Mahanjit, et al.
Publicado: (2022)

Investigator-initiated studies: Challenges and solutions
por: Konwar, Mahanjit, et al.
Publicado: (2018)

Cardiovascular and renal outcomes with sodium glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus: A system review and network meta-analysis
por: Tian, Lei, et al.
Publicado: (2022)

Renal outcomes with sodium-glucose cotransporters 2 inhibitors
por: Sun, Xiaoya, et al.
Publicado: (2022)

Sodium–glucose cotransporter 2 inhibitors: renal outcomes according to baseline albuminuria
por: Delanaye, Pierre, et al.
Publicado: (2021)

Sodium-glucose co-transporter-2 inhibitors: A cardiovascular outcome trial analysis
por: Suvarna, Viraj Ramesh
Publicado: (2021)

Surrogate cardiovascular outcomes with sodium-glucose co-transporter-2 inhibitors in women: An updated meta-analysis
por: Patoulias, Dimitrios, et al.
Publicado: (2021)

Sodium–glucose co-transporter 2 inhibitors for the treatment of cardio-renal syndrome
por: Cice, Gennaro, et al.
Publicado: (2022)

Renal safety of canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes mellitus
por: Desai, Mehul, et al.
Publicado: (2017)

Sodium–Glucose Cotransporter 2 Inhibitor Protection Against Adverse Cardiovascular and Renal Outcomes in Patients With Type 2 Diabetes
por: Shahady, Edward, et al.
Publicado: (2019)

The effect of sodium-glucose cotransporter 2 inhibitors in patients with chronic kidney disease with or without type 2 diabetes mellitus on cardiovascular and renal outcomes: A systematic review and meta-analysis
por: Reyes-Farias, Carlos Ignacio, et al.
Publicado: (2023)

Effects of sodium‐glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta‐analysis of randomized controlled trials
por: Zheng, Caiyun, et al.
Publicado: (2021)

Polypharmacy influences the renal composite outcome in patients treated with sodium‐glucose cotransporter 2 inhibitors
por: Kobayashi, Kazuo, et al.
Publicado: (2022)

Sodium–glucose co‐transporter‐2 inhibitor cardiovascular outcome trials and generalizability to English primary care
por: Hinton, W., et al.
Publicado: (2020)

Lessons from the Trials for the Desirable Effects of Sodium Glucose Co-Transporter 2 Inhibitors on Diabetic Cardiovascular Events and Renal Dysfunction
por: Wakisaka, Masanori, et al.
Publicado: (2019)

Sodium‐glucose co‐transporter‐2 inhibitors with and without metformin: A meta‐analysis of cardiovascular, kidney and mortality outcomes
por: Neuen, Brendon L., et al.
Publicado: (2020)

Cardiovascular Effects of Sodium Glucose Co-transporter-2 Inhibitors in Patients with Type 2 Diabetes Mellitus
por: Kumar, Surender, et al.
Publicado: (2019)

Therapeutic Effect of Sodium Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Renal Cell Carcinoma
por: Kuang, Haoyu, et al.
Publicado: (2017)

Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A protocol for systematic review and meta-analysis
por: Yu, Baisong, et al.
Publicado: (2021)

Cardiovascular outcomes in patients treated with sodium-glucose transport protein 2 inhibitors, a network meta-analysis of randomized trials
por: Tornyos, Dániel, et al.
Publicado: (2022)

Renal outcomes and all‐cause death associated with sodium‐glucose co‐transporter‐2 inhibitors versus other glucose‐lowering drugs (CVD‐REAL 3 Korea)
por: Koh, Eun Sil, et al.
Publicado: (2020)

The Effects of Sodium-Glucose Cotransporter-2 Inhibitors (SLGT-2i) on Cardiovascular and Renal Outcomes in Non-diabetic Patients: A Systematic Review
por: Giri Ravindran, Suganya, et al.
Publicado: (2022)

Comparative efficacy and safety of sodium–glucose cotransporter 2 inhibitors for renal outcomes in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis
por: Ma, Junhua, et al.
Publicado: (2023)

Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular outcomes in patients with atrial fibrillation and type 2 diabetes mellitus
por: Choi, Y, et al.
Publicado: (2023)

An evaluation of drug lag for new drugs approved by the Indian regulator relative to the United States, European Union, and Japanese regulatory agencies: A 15-year analysis (2004–2018)
por: Konwar, Mahanjit, et al.
Publicado: (2021)

Role of Selective Sodium-Glucose Co-Transporter-2 Inhibitors in Managing Cardio-Renal Complications in Type 2 Diabetes Mellitus: Beyond Glycemic Control
por: Onyali, Chike B, et al.
Publicado: (2021)

Clinical And Biochemical Outcomes Of Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors In Type 2 Diabetes Mellitus Patients
por: Saleem, Muhammad, et al.
Publicado: (2021)

Exposure–response relationships for the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin with regard to renal risk markers
por: Kroonen, Marjolein Y. A. M., et al.
Publicado: (2020)

Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study
por: Pasternak, Björn, et al.
Publicado: (2020)

Effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular outcomes in elderly patients with comorbid coronary heart disease and diabetes mellitus
por: XU, Hu, et al.
Publicado: (2021)

Mitochondria-Mediated Cardiovascular Benefits of Sodium-Glucose Co-Transporter 2 Inhibitors
por: Dabravolski, Siarhei A., et al.
Publicado: (2022)

Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors: Are They All the Same? A Narrative Review of Cardiovascular Outcome Trials
por: Williams, David M., et al.
Publicado: (2020)

A novel strategy for the treatment of diabetes mellitus - sodium glucose co-transport inhibitors
por: Niazi, Asfandyar Khan, et al.
Publicado: (2010)

Association of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Use With Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus Patients With Stabilized Acute Myocardial Infarction: A Propensity Score Matching Study
por: Chang, Ting-Yung, et al.
Publicado: (2022)

Sodium-glucose cotransporter 2 inhibitor effects on cardiovascular outcomes in chronic kidney disease
por: Shivakumar, Oshini, et al.
Publicado: (2020)

Clinical response to sodium glucose co‐transporter 2 inhibitor ipragliflozin in a patient with metastatic renal cell carcinoma
por: Izumi, Keita, et al.
Publicado: (2019)

Altered Renal Sodium Transporter Expression in an Animal Model of Type 2 Diabetes Mellitus
por: Oh, Yun Kyu, et al.
Publicado: (2007)

Adverse cardiovascular, limb, and renal outcomes in patients with diabetes after peripheral artery disease revascularization treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors
por: Lee, Hsin-Fu, et al.
Publicado: (2023)

Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis
por: Castellana, Marco, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cb1k11647g4k30opli2bsnsud8